Drug reference

Cyproterone acetate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 834, 835

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Hyper-sexuality in males | Sexual deviation in males ▶BY MOUTH ▶Adult: 50 mg twice daily, to be taken after food Prevention of tumour flare with initial gonadorelin analogue therapy ▶BY MOUTH ▶Adult (male): 200 mg daily in 2–3 divided doses for 5–7 days before initiation of gonadorelin analogue, followed by 200 mg daily in 2–3 divided doses for 3–4 weeks after initiation of gonadorelin analogue; maximum 300 mg per day. Long-term palliative therapy where gonadorelin analogues or orchidectomy contra-indicated, not tolerated, or where oral therapy preferred ▶BY MOUTH ▶Adult (male): 200–300 mg daily in 2–3 divided doses. Hot flushes with gonadorelin analogue therapy or after orchidectomy ▶BY MOUTH ▶Adult (male): Initially 50 mg daily, then adjusted according to response to 50–150 mg daily in 1–3 divided doses.

PDF pages 834, 835

Contra Indications

GENERAL CONTRA-INDICATIONS Dubin-Johnson syndrome. existing or history of thromboembolic disorders. malignant diseases (except for carcinoma of the prostate). meningioma or history of meningioma. previous or existing liver tumours (not due to metastases from carcinoma of the prostate). Rotor syndrome. wasting diseases (except for inoperable carcinoma of the prostate) SPECIFIC CONTRA-INDICATIONS ▶When used for hypersexuality Severe depression. severe diabetes (with vascular changes). sickle-cell anaemia

PDF page 835

Cautions

Diabetes mellitus. in prostate cancer, severe depression. in prostate cancer, sickle-cell anaemia. ineffective for male hypersexuality in chronic alcoholism (relevance to prostate cancer not known)

PDF page 835

Safety

Side Effects

▶Common or very common Depressed mood. dyspnoea. fatigue. gynaecomastia. hepatic disorders. hot ﬂush. hyperhidrosis. nipple pain. restlessness. weight change ▶Uncommon Skin reactions ▶Rare or very rare Galactorrhoea. neoplasms ▶Frequency not known Adrenocortical suppression. anaemia. azoospermia. hair changes. hypotrichosis. osteoporosis. sebaceous gland underactivity (may clear acne). thromboembolism SIDE-EFFECTS, FURTHER INFORMATION Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported (fatalities reported, usually after several months, at dosages of 100 mg and above). If hepatotoxicity is conﬁrmed, cyproterone should normally be withdrawn unless the hepatotoxicity can be explained by another cause such as metastatic disease (in which case cyproterone should be continued only if the perceived beneﬁt exceeds the risk).

PDF page 835

Hepatic Impairment

Manufacturer advises avoid (unless used for prostate cancer).

PDF page 835

Monitoring Requirements

▶Monitor blood counts initially and throughout treatment. ▶Monitor adrenocortical function regularly. ▶Monitor hepatic function regularly—liver function tests should be performed before and regularly during treatment and whenever symptoms suggestive of hepatotoxicity occur.

PDF page 835

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Cyproterone acetate (Non-proprietary) Cyproterone acetate 50 mg Cyproterone 50mg tablets | 56 tablet P £48.95 DT = £30.41 Cyproterone acetate 100 mg Cyproterone 100mg tablets | 84 tablet P £132.57 DT = £57.89 Endocrine system ▶Androcur (Bayer Plc) Cyproterone acetate 50 mg Androcur 50mg tablets | 60 tablet P £31.34 ▶Cyprostat (Bayer Plc) Cyproterone acetate 50 mg Cyprostat 50mg tablets | 160 tablet P £82.86 Cyproterone acetate 100 mg Cyprostat 100mg tablets | 80 tablet P £82.86 Thyroid disorders PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › THYROID STIMULATING HORMONES

PDF page 835

Clinical care

Patient And Carer Advice

Driving and skilled tasks Fatigue and lassitude may impair performance of skilled tasks (e.g. driving).

PDF page 835

Dose text by age group

Adult

50 mg twice daily, to be taken after food

First-line fragment. Read the complete Indications and Dose section above.

PDF page 834

Adult (male)

200 mg daily in 2–3 divided doses for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 835

Adult (male)

200–300 mg daily in 2–3 divided doses.

First-line fragment. Read the complete Indications and Dose section above.

PDF page 835

Adult (male)

Initially 50 mg daily, then adjusted

First-line fragment. Read the complete Indications and Dose section above.

PDF page 835

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Cyproterone acetate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 834, 835

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF pages 834, 835

Contra Indications

PDF page 835

Cautions

Diabetes mellitus. in prostate cancer, severe depression. in prostate cancer, sickle-cell anaemia. ineffective for male hypersexuality in chronic alcoholism (relevance to prostate cancer not known)

PDF page 835

Safety

Side Effects

PDF page 835

Hepatic Impairment

Manufacturer advises avoid (unless used for prostate cancer).

PDF page 835

Monitoring Requirements

PDF page 835

Dose and formulations

Medicinal Forms

PDF page 835

Clinical care

Patient And Carer Advice

Driving and skilled tasks Fatigue and lassitude may impair performance of skilled tasks (e.g. driving).

PDF page 835

Dose text by age group

Adult

50 mg twice daily, to be taken after food

First-line fragment. Read the complete Indications and Dose section above.

PDF page 834

Adult (male)

200 mg daily in 2–3 divided doses for

First-line fragment. Read the complete Indications and Dose section above.

PDF page 835

Adult (male)

200–300 mg daily in 2–3 divided doses.

First-line fragment. Read the complete Indications and Dose section above.

PDF page 835

Adult (male)

Initially 50 mg daily, then adjusted

First-line fragment. Read the complete Indications and Dose section above.

PDF page 835

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.